You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Feasibility and proof of concept of a dense, low cost, network of sensors driving Intelligent building Agents for air quality and energy control.
SBC: XMARK LABS, LLC Topic: 6Commercial buildings use 35% of the entire US energy output, and up to a third of that energy is wasted. Rapidly rising fuel costs, increasing concern about climate change, and policy directives from the Biden Administration are all driving the need for increased energy efficiency and the elimination of waste. At the same time, the COVID-19 pandemic has dramatically increased public awareness of t ...
SBIR Phase I 2023 Department of CommerceNational Institute of Standards and Technology -
Analytical Quality Management for 3D-Printed Small Molecule Drugs
SBC: INFRATRAC INC Topic: 2The promise of personalized medicine can be realized in part via point-of-care 3D drug printing, but only if there are reliable quality measures available. Children and seniors may need custom or easy-to-swallow doses, a need now addressed only in a limited way by ad-hoc in-pharmacy compounding. Compliance-targeted enhancements such as flavor and shape choices are particularly important for childr ...
SBIR Phase II 2023 Department of CommerceNational Institute of Standards and Technology -
Pharmaceutical development of longer-lasting brimonidine eye drops
SBC: Novus Vision LLC Topic: NEIPROJECT SUMMARY Glaucoma is the leading cause of irreversible blindness, impacting 80 million people worldwide. The only proven approach to prevent vision loss in glaucoma is the reduction of intraocular pressure (IOP), which is most commonly achieved by topical medications. Once daily (QD) prostaglandins are a typical first-line therapy, though the need for adjunctive therapy with other drug clas ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD
SBC: CREATIVE BIO-PEPTIDES INC Topic: NIA7. Project Summary ADRD dementias account for up to 25% of all dementias in patients older than 65 years and there is strong evidence of co-morbid pathologies caused by (amyloid β (Aβ), tau and α-synuclein (αSyn). The degree of AD- related pathology in Lewy Body Dementias (LBD) is moderate or severe in 50% of PDD and more than 70% of DLB patients have concomitant AD-related pathology so that t ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring
SBC: Axioforce LLC Topic: NIBIBPROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis
SBC: PROTHERA BIOLOGICS, INC. Topic: NICHDNecrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma
SBC: Sarya, LLC Topic: 102PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Treatment of status epilepticus and refractory status epilepticus with intravenous topiramate.
SBC: PREVEP, LLC Topic: NINDSAbstract Status epilepticus (SE) is a common neurologic emergency that fails to respond to first- and second-line anti-seizure medications (ASMs) in about one third of instances, thus progressing to refractory SE (RSE). Patients with RSE are at grave risk for neurological morbidity and mortality. The recently completed NIH-funded Established SE Treatment Trial (ESETT) highlights the need for impro ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Staph Aureus Vaccine
SBC: BIOLOGICAL MIMETICS, INC. Topic: NIAIDAbstract Methicillin-resistant Staphylococcus aureus is often considered the prototype hospital-acquired infection. In spite of the billions of dollars spent on preventive measures, estimates of the incidence are in the hundreds of thousands, with tens of thousands of people per year succumbing to disease in the USA alone. Prophylactic vaccines against S. aureus would have an enormous impact in th ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy
SBC: NEWVENTUREIQ LLC Topic: 102Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health